ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,306.04
0.02%
US Tech 100
18,387.60
0.38%
Dow Jones
38,852.86
-0.55%
Brent Oil
84.175
-0.18%
Bitcoin
68,477.69
0.27%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Taysha Gene Therapies Inc (TSHA) Quote

Taysha Gene Therapies Inc

Taysha Gene Therapies Inc (TSHA)

NASDAQ
3.25
0.01
(0.31%)
Closed May 28 4:00PM
Delayed by 15 minutes
3.15
-0.10
(-3.08%)
After Hours: 5:46PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
3.15
Bid
3.11
Ask
3.25
Volume
1,662,395
3.14 Day's Range 3.295
0.50 52 Week Range 3.89
Market Cap
609.49M
Previous Close
3.24
Open
3.24
Last Trade
5
@
3.2491
Last Trade Time
Financial Volume
$ 5,360,357
VWAP
3.2245
Average Volume (3m)
2,441,787
Shares Outstanding
186,960,193
Dividend Yield
-
PE Ratio
-5.46
Earnings Per Share (EPS)
-0.6
Revenue
15.45M
Net Profit
-111.57M

About Taysha Gene Therapies Inc

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and com... Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.tayshagtx.com
Headquarters
Dover, Delaware, USA
Founded
1970
Taysha Gene Therapies Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TSHA. The last closing price for Taysha Gene Therapies was $3.24. Over the last year, Taysha Gene Therapies shares have traded in a share price range of $ 0.50 to $ 3.89.

Taysha Gene Therapies currently has 186,960,193 shares outstanding. The market capitalization of Taysha Gene Therapies is $609.49 million. Taysha Gene Therapies has a price to earnings ratio (PE ratio) of -5.46.

TSHA Latest News

More News

Form 8-K - Current report

May 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14 2024
Edgar (US Regulatory)

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

Completed dosing in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102;...

May 14 2024
GlobeNewswire Inc.

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for...

May 07 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, May 03, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for...

May 03 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult...

May 02 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies...

April 05 2024
GlobeNewswire Inc.

Another Biotech Steals The Show Following Major Clinical Data Release

There was some pretty substantial news coming out of Dallas, TX this morning after a biotech company shared initial clinical data from the first pediatric patient from the REVEAL To read the full...

March 20 2024
AllPennyStocks.com

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained...

March 19 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.092.941176470593.063.2952.83517856603.00978107CS
40.6124.01574803152.543.2952.316047392.76942401CS
120.175.704697986582.983.432.0624417872.79525039CS
261.35751.83.551.3823270922.38257848CS
522.46356.521739130.693.890.527765592.31691528CS
156-19.46-86.068111455122.6126.990.512863772.83131757CS
260-19.1-85.842696629222.2533.840.510729293.28910457CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.08M
AWINAERWINS Technologies Inc
$ 8.99
(139.10%)
5.41M
INSMInsmed Inc
$ 48.107
(118.67%)
33.42M
GVVisionary Holdings Inc
$ 0.38
(90.00%)
10.33M
SOBRSOBR Safe Inc
$ 0.41
(82.22%)
130.83M
APDNApplied DNA Sciences Inc
$ 0.580601
(-70.82%)
9.45M
LUCYInnovative Eyewear Inc
$ 0.40
(-59.31%)
84.98M
MRAIMarpai Inc
$ 0.90
(-53.61%)
803.83k
TOIIWOncology Institute Inc
$ 0.021
(-52.60%)
293.22k
SHOTWSafety Shot Inc
$ 0.21
(-36.07%)
24.26k
PEGYPineapple Energy Inc
$ 0.2595
(45.70%)
676.58M
GWAVGreenwave Technology Solutions Inc
$ 0.0782
(-7.89%)
306.52M
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.07M
CRKNCrown Electrokinetics Corporation
$ 0.1073
(6.24%)
232.53M
OBLGOblong Inc
$ 0.21
(19.32%)
146.15M

TSHA Discussion

View Posts
FooBarAndGrill FooBarAndGrill 3 days ago
Taysha may have the real ONE-SHOT genetic cure. It may REALLY work.
Good luck getting any health insurance plan to list this $Million dollar shot in their drug formulary.
👍️0
Monksdream Monksdream 3 days ago
TSHA under $5
👍️0
glenn1919 glenn1919 2 months ago
TSHA..............................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA..READY TO PUSH TO 4.00
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA...HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
TSHA..here we go
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
TSHA NEXT BIO BEAST TO RUN TO 3.61 WATCH THE MAGIC
👍️0
FooBarAndGrill FooBarAndGrill 5 months ago
“Dosing the first pediatric patient with Rett syndrome marks an important step forward in our efforts to broaden the clinical evaluation of TSHA-102 to younger patients with earlier stages of Rett syndrome. We are pleased with our progress on expanding the study of TSHA-102 across a broad population of ages and stages of Rett syndrome to bring a potentially transformative treatment option to all patients and families suffering from this devastating disease,” said Sukumar Nagendran, M.D., President, and Head of R&D of Taysha. “The pediatric trial will build on our ongoing REVEAL adolescent and adult trial, where early data demonstrated improvements across multiple clinical domains in adult patients with the most advanced stage of disease. We also plan to expand our U.S. pediatric trial into the U.K. following the recent acceptance of our CTA by the MHRA.”
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
Estimated Enrollment : 18 participants
(was 12).
https://classic.clinicaltrials.gov/ct2/show/NCT05606614
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
“Following review of the initial clinical data from the first two adult patients treated with TSHA-102 and Chemistry, Manufacturing, and Controls (CMC) data, Health Canada has authorized our protocol amendment to include adolescent patients aged 12 years and older in the ongoing REVEAL Phase 1/2 adult trial,”
https://ih.advfn.com/stock-market/NASDAQ/taysha-gene-therapies-TSHA/stock-news/92678004/taysha-gene-therapies-announces-expanded-eligibili
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
The P1 TSHA-102 REVEAL Adult Study has been on a slow boat.
Hopefully, the Clinical Updates PR will give the push to finally complete enrollment of the 12 adult female Rett patients needed for the trial.
I'm guessing reluctance to enroll has been based on the one-time injection into the intrathecal space (directly into the Cerebral Spinal Fluid).
It's definitely worth the risk, IMO. Good Luck to All.
👍️0
bikaver bikaver 8 months ago
TSHA.....Definitely headed in the right direction now. A couple more days of downward momo would be great.
👍️0
make it happen make it happen 8 months ago
Cannacord Genuity and Truist Securities both lowered there price targets, never a good thing...
👍️0
make it happen make it happen 8 months ago
Think it's about there. I believe we flush under $3.00 and don't come back to the this price per share PPS till R/S. A ways away but see it happening. JMHO
👍️0
bikaver bikaver 8 months ago
TSHA.....kicking my butt.....next week is make or break!
👍️0
Triple nickle Triple nickle 9 months ago
Good call my .90 are looking ripe
👍️0
bikaver bikaver 9 months ago
Added 3.28 today.
👍️0
bikaver bikaver 9 months ago
TSHA.....Today, all day, was a bull trap. Tomorrow could be Free Falling Friday.
👍️0
bikaver bikaver 9 months ago
TSHA.....The buyers at 2.85-2.91 proves the phrase "There's a sucker born every minute." to be true.
👍️0
richme richme 9 months ago
Looks like the rocket exploded! Was tempted to buy; glad I did not!

Finally bought 2.19 for 6K shares; too soon; down more now to 2.14.
👍️0
Jess070283 Jess070283 9 months ago
Blast off at open?
👍️0
riha riha 9 months ago
at least i don't feel foolish now.

tomorrow though... i might.
👍️0
alchemytrader alchemytrader 9 months ago
be glad you didnt get any. hit 2.91 a/h.
👍️0
alchemytrader alchemytrader 9 months ago
2.85 RIP
👍️0
Triple nickle Triple nickle 9 months ago
Tif function
👍️0
riha riha 9 months ago
I can't get any shorts... fuck
👍️0
bikaver bikaver 9 months ago
TSHA..... added 2.10 short into this strong close.
👍️0
bikaver bikaver 9 months ago
TSHA.....short @ 1.79
👍️0
snave599 snave599 9 months ago
Because it's up 130%.That's why it's halted.
👍️0
Romiman Romiman 9 months ago
Halted 2 times already this morning
👍️0
make it happen make it happen 9 months ago
Hundreds of millions of shares being sold for $0.90 share structure is multiplying time over 3 massive dilution imho
👍️0
Awl416 Awl416 9 months ago
Taysha Gene Therapies Announces $150 Million Private Placement Financing
👍️0
ErnieBilco ErnieBilco 1 year ago
Between November 2022 and Feb 9th FMR LLC has shed over 700K shares.
👍️0
conix conix 1 year ago
Perspective

https://seekingalpha.com/article/4575072-taysha-fda-stuck-major-blow-to-plans?mailingid=30466606&messageid=2850&serial=30466606.1106
👍️0
ErnieBilco ErnieBilco 1 year ago
What a buying opportunity here this morning.
👍️0
scotsand scotsand 2 years ago
Grabbed more earlier today after doing further due diligence. Glta
👍️0
1hot toddy 1hot toddy 2 years ago
14,000 SHARE BUY @2.21 HUGE BUYS COMING IN $$$$$$$$$$$$$$$$$$$$$$$
👍️0
TechnicalAnalyst1984 TechnicalAnalyst1984 2 years ago
Thanks, Yeah bios suck that way, ATMs If you want to know my history, here is a recent post, you should see the details of this conversation:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170277591
👍️0
scotsand scotsand 2 years ago
Beating down this morning
👍️0
MiamiGent MiamiGent 2 years ago
Good luck, TA , These bios always put us on edge.

I'm similiarly in "high" on today's bio runner and I could use a drink! lol But I can't because I have to do my business accounting, tonight. Those two don't mix, lol

I was within 2 or 3 cents or stopping myself out and then it zoomed again. Crazy bios

Be strong.. and smart.
👍️0
subslover subslover 2 years ago
That is good your out. I can almost guarantee class action lawsuits for misleading the public.
👍️0
TechnicalAnalyst1984 TechnicalAnalyst1984 2 years ago
Yeah I'm out. Insider Financial people, Alex or whoever are a bunch of idiots!
👍️0
subslover subslover 2 years ago
aysha Drops on Stock Offering
October 26 2022 - 08:18AM
TipRanks
Alert
Print
Share On Facebook
Gene therapy company Taysha Gene Therapies’ (NASDAQ:TSHA) shares are tanking in the pre-market session today on the announcement of an underwritten public offering of $30 million. All the shares on offer are being sold by Taysha and underwriters will have the option to acquire an additional 15% of shares at the same terms over the next 30 days. The development comes fresh on the heels of Taysha announcing a major deal with Astellas Pharma that will see the latter making a $50 million strategic investment in Taysha for a 15% stake.
https://www.tipranks.com/news/taysha-drops-on-stock-offering?utm_source=advfn.com&utm_medium=referral
👍️0
TechnicalAnalyst1984 TechnicalAnalyst1984 2 years ago
What I'm not understanding is this Subs: Insider Financial claims Taysha has cancelled an offering but yesterday's PR indicates they are not! Which is it?
👍️0
TechnicalAnalyst1984 TechnicalAnalyst1984 2 years ago
I usually do not touch bio tech companies but took a chance with this one picking up 9387 shares at $2.45 this morning; we'll see
👍️0
subslover subslover 2 years ago
HOD was $3.00 enormous move
👍️0
subslover subslover 2 years ago
HOD was $3.00 enormous move
👍️0
KOmani KOmani 2 years ago
Always happens these days.

You have to trade with the reality that it happens 90% of the time.

However, there wasn't much of a flush at the end of the day.

Have to wonder if it wasn't pre-sold this time.
👍️0

Your Recent History

NASDAQ
TSHA
Taysha Gene Therapies
BIT
S5SMOD
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved